Stock info Vertex Pharma | Filter  Basic-Info

Stock: Vertex Pharma (US Tech), ISIN: US92532F1003

Last Price 415.71 Max Price 446.08
Min Price 308.47 1 Year return 89.30
Sector Health Care Subsector Biotechnology
Annual report 2020

Vertex Pharma Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. Vertex Pharma ’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex Pharma ’s product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex Pharma co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline . Vertex Pharma ’s stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US92532F1003/ Symbol: VRTX).

Loading...

Contact info:Zip Code: ProvidencePostbox: P.O Box 43023 Country: USAPhone: 1 781-575-2879Website: www.vrx.com

Sector Review Vertex Pharma

Loading...
Year Turnover Total sector Market share
2019 4,163 141,925 2.93 %
2020 6,206 170,231 3.65 %
2021 7,574 252,886 3.00 %
2022 8,931 238,500 3.74 %
2023 0 0 0.00 %

Advice Vertex Pharma

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
July 22, 2020 Deutsche Bank Vertex Pharma Buy 305.00 10.87 %
July 16, 2020 Jefferies & Co. Vertex Pharma Buy 340.00 20.04 %
July 09, 2020 Morgan Stanley Vertex Pharma Hold 300.00 9.38 %
June 12, 2020 Citigroup Vertex Pharma Buy 325.00 16.35 %
April 30, 2020 Jefferies & Co. Vertex Pharma Buy 295.00 27.63 %
April 30, 2020 Cowen and Company Vertex Pharma Buy 265.00 -2.59 %
April 30, 2020 Robert W. Baird Vertex Pharma Buy 245.00 -10.96 %
January 27, 2020 Cowen and Company Vertex Pharma Buy 250.00 4.54 %
January 09, 2020 Oppenheimer & Co Vertex Pharma Buy 265.00 -2.59 %
January 09, 2020 Citigroup Vertex Pharma Buy 265.00 14.47 %
December 20, 2019 Jefferies & Co. Vertex Pharma Buy 275.00 15.60 %
November 22, 2019 Jefferies & Co. Vertex Pharma Buy 250.00 15.21 %
November 21, 2019 BMO Capital Markets Vertex Pharma Buy 248.00 -9.62 %
November 21, 2019 Jefferies & Co. Vertex Pharma Buy 250.00 13.46 %
November 21, 2019 Credit Suisse Vertex Pharma Buy 231.00 -17.69 %
November 01, 2019 Stifel Vertex Pharma Buy 229.00 -18.72 %
November 01, 2019 RBC Capital Markets Vertex Pharma Buy 235.00 -15.69 %
October 23, 2019 JP Morgan Vertex Pharma Buy 218.00 -24.71 %
October 23, 2019 Bank of America Merrill Lynch Vertex Pharma Buy 235.00 -15.69 %
October 23, 2019 Citigroup Vertex Pharma Buy 225.00 6.05 %
October 23, 2019 Credit Suisse Vertex Pharma Buy 221.00 4.35 %
October 23, 2019 BMO Capital Markets Vertex Pharma Buy 232.00 8.89 %
September 24, 2019 Jefferies & Co. Vertex Pharma Buy 220.00 -21.63 %
September 23, 2019 Jefferies & Co. Vertex Pharma Buy 220.00 -20.00 %
August 02, 2019 Stifel Vertex Pharma Buy 211.00 -29.65 %
August 02, 2019 Needham & Co. Vertex Pharma Hold
August 01, 2019 RBC Capital Markets Vertex Pharma Buy 213.00 -28.43 %
August 01, 2019 JP Morgan Vertex Pharma Buy 209.00 -30.89 %
May 21, 2019 Credit Suisse Vertex Pharma Buy 209.00 -35.95 %
March 08, 2019 Oppenheimer & Co Vertex Pharma Buy 230.00 1.19 %
February 08, 2019 Morgan Stanley Vertex Pharma Buy 220.00 -8.69 %
February 06, 2019 JP Morgan Vertex Pharma Buy 209.00 -15.92 %
February 06, 2019 Cowen and Company Vertex Pharma Buy 220.00 -10.12 %
December 20, 2018 Morgan Stanley Vertex Pharma Buy 210.00 -3.64 %
July 26, 2018 RBC Capital Markets Vertex Pharma Buy 203.00 16.09 %
April 30, 2018 Morgan Stanley Vertex Pharma Buy 207.00 16.98 %
April 30, 2018 Leerink Swann & Company Vertex Pharma Buy 175.00 -55.35 %
April 30, 2018 RBC Capital Markets Vertex Pharma Buy 202.00 14.92 %
February 13, 2018 Credit Suisse Vertex Pharma Buy 196.00 6.52 %
February 13, 2018 Deutsche Bank Vertex Pharma Buy 197.00 7.00 %



News Vertex Pharma

Analysts expect revenue increase Vertex Pharma

Vertex Pharma will announce it's last quarter's results tomorrow. For this year the company, based in Boston revenue will be around 6.99 billion USD. This is according to the average of the analysts' estimates. This is rather significant more than 2021's revenue...

Analysts expect over 2020 rising revenue Vertex Pharma

For this year Vertex Pharma's revenue will be around 6 billion USD. This is according to the average of the analysts' estimates. This is quite more than 2019's revenue of 4,16 billion USD. Historical revenues and results Vertex Pharma plus estimates 2020 The...

Vertex Pharma huge outperformer in American biotech sector

In the recent years Vertex Pharma had a very positive price momentum. Because of the huge return over the past 5 years of 161 percent the share belongs to the top of the biotech companies. Shares of the sector yielded the past 5 years a gain of approximately 191...

Analysts foresee more revenue Vertex Pharma

Tomorrow the American Vertex Pharma will report its past quarter's results. Over the current book year the total revenue will be 3,01 billion USD (consensus estimates). This is quite more than 2017's revenue of 2,49 billion USD. Historical revenues and results...

Analysts foresee more revenue Vertex Pharma

Tomorrow Vertex Pharma will publish its past quarter's results. For this year Vertex Pharma 's revenue will be around 2,33 billion USD. This is according to the average of the analysts' estimates. This is rather significant more than 2016's revenue of 1,7 billion...

Annual reports Vertex Pharma

2017 2018 2019 2020 2021

Profile Vertex Pharma

Vertex Pharma

(US92532F1003)/ VRTX

The past year was a profitable year for the Vertex Pharma investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Vertex Pharma. The stock lost around 36 percent. Over the period from December 2011 till December 2016 the stock rose on average 131 percent. Vertex Pharma's revenues between 2011 and 2015 were very fluctuating and moved between 17,46 million dollars and 72,59 million dollars. Vertex Pharma's net incomes between 2011 and 2015 were very volatile through the time and moved between -3,15 million dollars and -28,54 million dollars.

Vertex Pharma is active in the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The American company didn't pay out any dividends (in the past 5 years).

Vertex Pharma' balance mostly consists of equity

Last year the balance sheet of the American company was worth 86,69 million dollars. Of the total balance sheet 55 million dollars (63,44 percent) was financed by debt. As per the end of 2015 Vertex Pharma's price/earnings-ratio equaled 0. So investors paid for 1 stock 0 times the earnings per share of 2015. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 6,38 billion dollars. At the end of 2015 the American company had around 52,38 million stocks listed.

All Vertex Pharma's financial reports are available here. More information about Vertex Pharma can be found it's website. .


Results Vertex Pharma

Results
2015
2016
2017
2018
2019
2020
Revenue
1,032
1,702
2,489
3,048
4,163
6,206
Costs
1,589
1,814
2,225
951
2,986
3,494
Profit
-556
-112
263
2,096
1,177
2,712
Margin of profit
-53.89
-6.58
10.58
68.79
28.27
43.70
ROI
-59.19
-9.69
12.97
47.27
19.34
31.22

Balance Vertex Pharma

Balance
2015
2016
2017
2018
2019
2020
Equity
940
1,157
2,029
4,435
6,085
8,687
Debt
1,559
1,740
1,517
1,811
2,233
3,065
Total assets
2,499
2,897
3,546
6,246
8,318
11,752
Solvency
37.62
39.93
57.21
71.01
73.15
73.92
Cash
1,042
1,435
2,089
3,168
3,808
6,659
Cashflow
-365
236
845
1,270
1,569
3,254
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
-0.23
0.14
0.56
0.70
0.70
1.06

Details Vertex Pharma

Details
2016
2017
2018
2019
2020
Price
125.83
73.67
149.86
165.71
218.95
Eps
-0.46
1.04
8.09
4.51
10.29
Price/earnings-ratio
-273.54
70.84
18.52
36.74
40.40
Dividend
0.0
0.0
0.0
0.0
Dividend %
0.00 %
0.00 %
0.00 %
0.00 %
Payout %
0.0
0.0
0.0
0.0
Book value
4.66
8.01
17.38
23.50
33.42
Market to book
0.04
0.11
0.12
0.14
0.08
Cashflow per stock
0.95
3.34
4.98
6.06
12.52
Stocks
248
253
255
259
260
Market Cap
31.243.65
18.657.18
38.240.08
42.917.73
108.038.87

Dividend Vertex Pharma


Price info Vertex Pharma

Date
Price
22 Mar 2024
415.71
18 Mar 2024
407.69
15 Mar 2024
408.77
12 Mar 2024
414.47
11 Mar 2024
413.59
09 Mar 2024
413.59
07 Mar 2024
411.85
01 Mar 2024
420.74
29 Feb 2024
426.97
27 Feb 2024
433.48
22 Feb 2024
419.63
21 Feb 2024
420.64
20 Feb 2024
422.20
15 Feb 2024
417.88
14 Feb 2024
416.04
13 Feb 2024
418.53
09 Feb 2024
423.06
08 Feb 2024
419.08
07 Feb 2024
416.13
06 Feb 2024
428.89
05 Feb 2024
424.68
01 Feb 2024
433.38
31 Jan 2024
446.08
30 Jan 2024
435.82
27 Jan 2024
430.17
25 Jan 2024
427.56
24 Jan 2024
439.70
23 Jan 2024
440.11
16 Jan 2024
433.40
11 Jan 2024
423.76